In September 2022, Sesen Bio entered into a definitive merger agreement with Carisma Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Following extensive engagement with Sesen Bio stockholders, the companies amended the merger agreement in December 2022 to deliver greater value in connection with closing.
Direct and immediate value ($0.34/share1)
A well-funded company developing groundbreaking therapies for a wide range of cancers ($0.40/share3)
Additional potential value via a Contingent Value Right (CVR) related to proceeds from any sale of Vicineum and Sesen Bio preclinical assets in addition to any proceeds from the milestone payment under the Roche Asset Purchase Agreement ($0.14/share5)
The Sesen Bio Board of Directors unanimously approved the pending merger with Carisma Therapeutics and recommends stockholders vote “FOR” all agenda items by telephone, internet or mail in advance of the special meeting on March 2, 2023.How to Vote